Who are 200mg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nevanac, DIPHENHYDRAMINE CITRATE, Xibrom, Excedrin Extra Strength Pain Reliever, Mobic, Celebrex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/200mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

200mg — Competitive Intelligence Brief

200mg (200mg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal Anti-inflammatory Drug [EPC].

marketed Nonsteroidal Anti-inflammatory Drug [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

200mg (200mg) — CSPC ZhongQi Pharmaceutical Technology Co., Ltd..

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
200mg TARGET	200mg	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]
Nevanac	NEPAFENAC	Harrow Health	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 2	2005-01-01
DIPHENHYDRAMINE CITRATE	DIPHENHYDRAMINE CITRATE		marketed	Nonsteroidal Anti-inflammatory Drug [EPC]		2005-01-01
Xibrom	BROMFENAC	Bausch Health	marketed	Nonsteroidal Anti-inflammatory Drug	Prostaglandin G/H synthase 2	2005-01-01
Excedrin Extra Strength Pain Reliever	NSAID	Haleon Us Holdings	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Cyclooxygenase	2004-01-01
Mobic	MELOXICAM	Boehringer Ingelheim	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 2	2000-01-01
Celebrex	celecoxib	Pfizer Inc. (originally Searle/Pharmacia)	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	COX-2	1998-12-31

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-05-26 — Mobic · 10709713 · Method of Use · US
2030-05-26 — Mobic · 9974746 · Formulation · US
2030-05-26 — Mobic · 11253478 · Formulation · US
2030-08-31 — Mobic · 8545879 · Formulation · US
2033-03-31 — Mobic · 9526734 · Formulation · US
2035-03-31 — Mobic · 9808468 · Method of Use · US
2035-03-31 — Mobic · 9649318 · Formulation · US
2036-05-27 — Celebrex · 10722456 · Formulation · US
2036-05-27 — Celebrex · 10376527 · Formulation · US
2036-05-27 — Celebrex · 9795620 · Formulation · US
2036-05-27 — Celebrex · 9949990 · Formulation · US
2036-05-27 — Celebrex · 10799517 · Formulation · US
2036-05-27 — Celebrex · 9572819 · Formulation · US
2039-03-08 — Mobic · 11458145 · Method of Use · US
2039-03-08 — Mobic · 10881663 · Method of Use · US
2040-07-19 — Mobic · 12059423 · Compound · US
2041-07-31 — Mobic · 12263176 · Formulation · US

Sponsor landscape (Nonsteroidal Anti-inflammatory Drug [EPC] class)

· 8 drugs in this class
Pfizer · 2 drugs in this class
Assiut University · 1 drug in this class
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
Centro Hospitalar Lisboa Ocidental · 1 drug in this class
Dartmouth-Hitchcock Medical Center · 1 drug in this class
Dr. Vishwanath Karad MIT World Peace University · 1 drug in this class
Dr. Reddy's Laboratories Limited · 1 drug in this class
Generic (originally Boots Group) · 1 drug in this class
Boehringer Ingelheim · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 200mg — Competitive Intelligence Brief. https://druglandscape.com/ci/200mg. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab